ghk cu europe Peptides are everywhere right now — but do you actually understand how they work and why treatments such as GHK-Cu are becoming one of the most talked-about innovations in aesthetics? Join us GHK-Cu | Copper Peptide EU

Clinical Information Evidence-based details for healthcare providers Use as directed by your healthcare provider

Phase 2 trial data for the CagriSema combination (cagrilintide 2.4mg + semaglutide 2.4mg) demonstrated approximately 15.6% mean weight reduction at 32 weeks substantially exceeding semaglutide alone and positioning amylin/GLP-1 dual agonism as a competitive research frontier alongside GIP/GLP-1 and triple agonist approaches

The dendrites of the new neurons branch toward the molecular layer as the axon moves into the CA3 region (Hastings and Gould, 1999)

doi: 10.1038/s41598-021-91793-0

Phase I clinical trial in healthy volunteers to study safety and pharmacokinetics of BPC-157, a pentadecapeptide from gastric source.